ClinicalTrials.gg

RAPT Therapeutics, Inc. clinical trials

Acquired by GlaxoSmithKline, Mar 3, 2026 · source ↗

The registry lists 8 studies whose lead sponsor is RAPT Therapeutics, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 6, 2026.

Before and after it joined GlaxoSmithKline

First submitted before RAPT Therapeutics, Inc. became part of GlaxoSmithKline
8
First submitted after RAPT Therapeutics, Inc. became part of GlaxoSmithKline
0
Unclear, or no submission date
0

By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.

What it is testing

The drugs RAPT Therapeutics, Inc.’s studies test, most studies first; none is open now — 3 drugs with a page of their own. Each count opens the studies in search.

Studies, none open

Coming up

1 of RAPT Therapeutics, Inc.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. D
  3. J’27
  4. F
  5. 1M
  6. A
  7. M
  8. J
  9. J
  10. A
  11. S
  12. O
  13. N

Add it to your calendar (.ics) → With an account.

All 8 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Under way, not recruiting113%
  • Completed338%
  • Stopped early450%

Phase

  • Phase 25
  • Phase 14

Where

  • United States8
  • Canada2
  • Australia2
  • Korea, Republic of1
  • Hong Kong1
  • Taiwan1

Over the years

  1. 15
  2. 16
  3. 17
  4. 18
  5. 19
  6. 20
  7. 21
  8. 22
  9. 223
  10. 24
  11. 25
  12. 026

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

  • RAPT Therapeutics, Inc.7 studies
  • RAPT Therapeutics, Inc., a member of the GSK plc group of companies1 study

Something wrong with this grouping? Tell us on the GlaxoSmithKline page.

Studies

Recruiting first, then most recently updated. Showing 8 of 8. All GlaxoSmithKline studies →